Institutional members access full text with Ovid®

New Type of Drug for Psoriatic Arthritis

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: July 2014 - Volume 114 - Issue 7 - p 23
doi: 10.1097/01.NAJ.0000451678.43576.ba
Drug Watch

* Apremilast (Otezla) is a phosphodiesterase-4 inhibitor that has been approved for use in the treatment of active psoriatic arthritis. Apremilast increases intracellular cyclic adenosine monophosphate, decreasing the levels of several proinflammatory mediators. The most common adverse effects are diarrhea, headache, and nausea. Apremilast may induce or exacerbate depression; serious depression is possible, although not common. Apremilast can also produce significant weight loss.

© 2014 Lippincott Williams & Wilkins. All rights reserved.